EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieMultizentrische StudieOpen Access

Specimen PET-CT Imaging for Intraoperative Margin Assessment in Early-Stage Breast Cancer

Menekse Göker, Markus Hahn, Ximena Elzo Kraemer, Hakima Harrach, Marian Vanhoeij, Glenn Vergauwen, Koen Van de Vijver, Kathia De Man, Fabian Schmidt, Selin Guergan, Valérie Vergucht, Rosa Di Micco und 2 weitere

JAMA Surgery · 01.08.2026 · 161 (8) · 785

DOI: 10.1001/jamasurg.2026.2090 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift JAMA Surgery, erschienen am 01.08.2026. Verfasst von Menekse Göker und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Ductal, Breast, Margins of Excision, Mastectomy, Segmental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Positive margins occur in 12% to 30% of breast-conserving surgeries and are associated with increased local recurrence risks. Accurate and efficient intraoperative margin assessment, therefore, remains an unmet clinical need.

Objective

To evaluate the success rate of intraoperative specimen positron emission tomography (PET)–computed tomography (CT) imaging in addressing positive margins in patients with invasive ductal carcinoma. Design, Setting, and Participants This was an interventional, multicenter, nonrandomized clinical trial that recruited patients from June 2022 to March 2025. Patients were followed up 2 weeks after surgery. Six European breast cancer centers participated and integrated specimen PET-CT imaging into their routine surgical flow. The analysis included eligible patients with early-stage breast cancer scheduled for breast-conserving surgery.

Interventions

Patients received an intravenous injection of low-dose 18 F-fluorodeoxyglucose (FDG; 0.8 MBq/kg). After tumor excision, the specimen was imaged intraoperatively using a dedicated specimen PET-CT scanner. Surgeons interpreted PET-CT images intraoperatively, and additional tissue was excised when margins were deemed suspicious to achieve final negative margins. Main Outcomes and Measures The primary outcome was the success rate of specimen PET-CT in addressing positive margins for the invasive component in patients undergoing breast-conserving surgery for invasive ductal carcinoma. Secondary outcomes included success rates in other breast cancer subtypes, final positive margin rates, reoperation rates, and diagnostic performance using histopathology as the reference standard.

Results

The analysis cohort consisted of 148 female patients with a median (IQR) age of 65 (53-73) years and a median (IQR) preoperative tumor size of 17 (12-22) mm. For the invasive component of invasive ductal carcinoma, success rates increased from 83.3% (70 of 84 patients) without intraoperative margin assessment (IMA) to 86.9% (73 of 84 patients) with routine margin assessment and to 95.2% (80 of 84 patients) with specimen PET-CT ( P < .001 vs no IMA). Across all study groups, success rates improved from 76.4% (113 of 148 patients) without IMA to 81.8% (121 of 148 patients) with routine margin assessment techniques and to 91.9% (136 of 148 patients) with specimen PET-CT ( P < .001 vs no IMA; P = .009 vs standard-of-care IMA). Conclusions and Relevance Study findings show that specimen PET-CT imaging was associated with an improvement in the assessment of positive margins for invasive component in patients undergoing conserving surgery for early breast cancer. The use of this integrated approach might lead to a substantial reduction of re-excision rates after breast-conserving surgery. Trial Registration ClinicalTrials.gov Identifier: NCT04999917

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Ductal, BreastMargins of ExcisionMastectomy, SegmentalPositron Emission Tomography Computed TomographyAgedFemaleHumansMiddle AgedFluorodeoxyglucose F18Neoplasm StagingRadiopharmaceuticals

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Ghent University Hospital, Ghent, Belgium.
  • Cancer Research Institute Ghent, Ghent, Belgium.
  • Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
  • Integrated Cancer Center Ghent, Department of Medical Oncology, Maria Middelares Hospital, Ghent, Belgium.
  • Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany.
  • Department of Oncological, Thoracic and Transplant Surgery, UZ Brussel (University Hospital Brussels), Brussels, Belgium.

Zitieren

APA

Göker, M., Hahn, M., Kraemer, X. E., Harrach, H., Vanhoeij, M., Vergauwen, G., Van de Vijver, K., De Man, K., Schmidt, F., Guergan, S., Vergucht, V., Di Micco, R., Cisternino, G., & Gentilini, O. D. (2026). Specimen PET-CT Imaging for Intraoperative Margin Assessment in Early-Stage Breast Cancer. JAMA Surgery, 161(8), 785. https://doi.org/10.1001/jamasurg.2026.2090

Vancouver

Göker M, Hahn M, Kraemer XE, Harrach H, Vanhoeij M, Vergauwen G, et al. Specimen PET-CT Imaging for Intraoperative Margin Assessment in Early-Stage Breast Cancer. JAMA Surgery. 2026;161(8):785. doi:10.1001/jamasurg.2026.2090

BibTeX
@article{Gker2026,
  author = {Göker, Menekse and Hahn, Markus and Kraemer, Ximena Elzo and Harrach, Hakima and Vanhoeij, Marian and Vergauwen, Glenn and Van de Vijver, Koen and De Man, Kathia and Schmidt, Fabian and Guergan, Selin and Vergucht, Valérie and Di Micco, Rosa and Cisternino, Giovanni and Gentilini, Oreste Davide},
  title = {Specimen PET-CT Imaging for Intraoperative Margin Assessment in Early-Stage Breast Cancer},
  journal = {JAMA Surgery},
  year = {2026},
  volume = {161},
  number = {8},
  pages = {785},
  doi = {10.1001/jamasurg.2026.2090}
}
Kostenlos starten →